Cargando…

Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions

Vesicular monoamine transporters (VMATs) are key regulators of neurotransmitter release responsible for controlling numerous physiological, cognitive, emotional, and behavioral functions. They represent important therapeutic targets for numerous pathological conditions. There are two isoforms of VMA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alwindi, Malik, Bizanti, Ariege
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687066/ https://www.ncbi.nlm.nih.gov/pubmed/38034713 http://dx.doi.org/10.1016/j.heliyon.2023.e22413

Ejemplares similares

Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas
por: Saisho, Yoshifumi, et al.
Publicado: (2008)

Functional genetic variants in the vesicular monoamine transporter 1 (VMAT1) modulate emotion processing
por: Lohoff, Falk W., et al.
Publicado: (2013)

The ins and outs of vesicular monoamine transporters
por: Yaffe, Dana, et al.
Publicado: (2018)

Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population
por: Richards, Misty, et al.
Publicado: (2006)

No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease
por: Tian, LinLin, et al.
Publicado: (2012)

Vesicular monoamine transporter, type 2 (vmat2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas
por: Freeby, Matthew, et al.
Publicado: (2012)

Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent
por: Jiang, Donglang, et al.
Publicado: (2019)

Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management
por: Sreeram, Venkatesh, et al.
Publicado: (2019)

A Brief Review on the Role of Vesicular Monoamine Transporter(2) Inhibitors in Hyperkinetic Movement Disorders
por: NIKKHAH, Ali
Publicado: (2021)

Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease
por: Brighina, Laura, et al.
Publicado: (2013)

Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors
por: Caroff, Stanley N.
Publicado: (2020)

Dopamine D(1), D(2), D(3) Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human Brain
por: Sun, Jianjun, et al.
Publicado: (2012)

Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters
por: Kölby, L, et al.
Publicado: (2003)

Selective Knockout of the Vesicular Monoamine Transporter 2 (Vmat2) Gene in Calbindin2/Calretinin-Positive Neurons Results in Profound Changes in Behavior and Response to Drugs of Abuse
por: König, Niclas, et al.
Publicado: (2020)

An Unusual Association between Neurofibromatosis Type 1 and Diffuse B Cell Lymphoma
por: Bizanti, Anas, et al.
Publicado: (2021)

Differential Localization of Vesicular Acetylcholine and Monoamine Transporters in PC12 Cells but Not CHO Cells
por: Liu, Yongjian, et al.
Publicado: (1997)

An Acidic Motif Retains Vesicular Monoamine Transporter 2 on Large Dense Core Vesicles
por: Waites, Clarissa L., et al.
Publicado: (2001)

Tyrosine Hydroxylase, Vesicular Monoamine Transporter and Dopamine Transporter mRNA Expression in Nigrostriatal Tissue of Rats with Pedunculopontine Neurotoxic Lesion
por: Blanco-Lezcano, Lisette, et al.
Publicado: (2018)

Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients
por: Xu, San San, et al.
Publicado: (2018)

A Functional Vesicular Monoamine Transporter 1 (VMAT1) Gene Variant Is Associated with Affect and the Prevalence of Anxiety, Affective, and Alcohol Use Disorders in a Longitudinal Population-Representative Birth Cohort Study
por: Vaht, Mariliis, et al.
Publicado: (2016)

Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells
Publicado: (1994)

A Glial Variant of the Vesicular Monoamine Transporter Is Required To Store Histamine in the Drosophila Visual System
por: Romero-Calderón, Rafael, et al.
Publicado: (2008)

Preliminary Evidence of Apathetic-Like Behavior in Aged Vesicular Monoamine Transporter 2 Deficient Mice
por: Baumann, Aron, et al.
Publicado: (2016)

Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson
por: Pifl, Christian, et al.
Publicado: (2023)

Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism
por: Beauchamp, Leah C., et al.
Publicado: (2020)

Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men
por: Yang, Xinglong, et al.
Publicado: (2015)

A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2
por: Huang, Zih-Rou, et al.
Publicado: (2016)

Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats
por: Hiranita, Takato
Publicado: (2015)

Elevated Levels of the Vesicular Monoamine Transporter and a Novel Repetitive Behavior in the Drosophila Model of Fragile X Syndrome
por: Tauber, John M., et al.
Publicado: (2011)

Argon blocks the expression of locomotor sensitization to amphetamine through antagonism at the vesicular monoamine transporter-2 and mu-opioid receptor in the nucleus accumbens
por: David, H N, et al.
Publicado: (2015)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by (18)F-FP-(+)-DTBZ PET
por: Lin, Kun-Ju, et al.
Publicado: (2013)

Precise CRISPR-Cas9-mediated mutation of a membrane trafficking domain in the Drosophila vesicular monoamine transporter gene
por: Asuncion, James D., et al.
Publicado: (2023)

Improved Working Memory but No Effect on Striatal Vesicular Monoamine Transporter Type 2 after Omega-3 Polyunsaturated Fatty Acid Supplementation
por: Narendran, Rajesh, et al.
Publicado: (2012)

Essential role of vesicular nucleotide transporter in vesicular storage and release of nucleotides in platelets
por: Hiasa, Miki, et al.
Publicado: (2014)

Human-specific mutations in VMAT1 confer functional changes and multi-directional evolution in the regulation of monoamine circuits
por: Sato, Daiki X., et al.
Publicado: (2019)

Expression of Vesicular Nucleotide Transporter in Rat Odontoblasts
por: Ikeda, Erina, et al.
Publicado: (2016)

Induction of VMAT-1 and TPH-1 Expression Induces Vesicular Accumulation of Serotonin and Protects Cells and Tissue from Cooling/Rewarming Injury
por: Talaei, Fatemeh, et al.
Publicado: (2012)

A novel missense variant in SLC18A2 causes recessive brain monoamine vesicular transport disease and absent serotonin in platelets
por: Padmakumar, Manisha, et al.
Publicado: (2019)

Methylone and Monoamine Transporters: Correlation with Toxicity
por: Sogawa, Chiharu, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gj919k1nvaiiqmj9j95ahh844i